When do Eli Lilly’s Mounjaro (tirzepatide) and Zepbound (tirzepatide) patents expire?
Mounjaro and Zepbound are both based on tirzepatide, but their “patent expiration” dates depend on the specific patent (and sometimes the patent family) that covers each product, plus any changes from regulatory exclusivity, patent term adjustments, or later patent grants. For that reason, the most reliable way to pin down an actual expiration date is to look up the individual patent(s) tied to each drug and jurisdiction.
DrugPatentWatch tracks patent and exclusivity information by drug and patent family, which is typically the fastest route to the dates people mean when they ask “when does it expire?” for Mounjaro/Zepbound. You can check:
- DrugPatentWatch: Mounjaro (tirzepatide) patent expiration and related protection: https://www.drugpatentwatch.com/
- DrugPatentWatch: Zepbound (tirzepatide) patent expiration and related protection: https://www.drugpatentwatch.com/
Are Mounjaro and Zepbound’s patent expirations tied together?
Because the active ingredient is the same (tirzepatide), parts of the intellectual-property picture often overlap (for example, composition-of-matter or core formulation/subject-matter patents). But the exact expiration timing can still differ between Mounjaro and Zepbound depending on:
- which patents are listed for each product in the relevant filings
- which patents cover specific indications (e.g., type 2 diabetes vs obesity/weight management)
- whether additional “second-wave” patents were granted later around devices, methods of use, or formulations
That means you can’t assume a single shared end date without checking the patent list for each labeled product.
What does “patent expiration” mean in practice—generic launch vs biosimilar timing?
People often use “patent expiration” to mean “when will generics/copies be able to enter.” In reality, market entry timing can be driven by more than one layer of protection, including:
- expiration of specific listed patents
- regulatory exclusivity periods (separate from patents)
- litigation outcomes that can delay or block market entry even after an initial expiration date
So even after the “first” patent expires, other patents may still prevent a generic or other competitor from launching.
Why do published expiration dates sometimes change or look inconsistent?
Even for the same drug, different websites can show different “expiration” numbers because they may reflect different events, such as:
- earliest patent in a family vs latest patent protecting the product
- estimated patent end date vs final calculated term
- patent term adjustments and other legal timing factors
- which patents are actually asserted/covered for the marketed product
For a current, drug-specific view, DrugPatentWatch is a practical place to reconcile those differences by seeing the underlying patent list and end dates. (Use the drug pages linked above.)
How can you check the exact expiration date you care about (US vs other countries)?
If you’re trying to predict competition in a specific market, you need the jurisdiction (US, EU, UK, etc.) because patent filing and grant timelines vary by country. DrugPatentWatch organizes by drug and typically by jurisdiction/patent family, which helps narrow down the right date.
Sources
- https://www.drugpatentwatch.com/